Claims
- 1. A method for immobilizing an affinity ligand onto a substrate comprising,
a) subjecting said substrate to a plasma treatment; b) subjecting said substrate to a silanization treatment; and c) subjecting said substrate to a crosslinking treatment.
- 2. The method of claim 1, whereby said substrate is a silicon substrate.
- 3. The method of claim 2, whereby said silicon substrate is a polydimethylsiloxane substrate.
- 4. The method of claim 1, whereby said step of subjecting said substrate to a silanization treatment includes subjecting said substrate to a silane selected from the group comprising aminosilane, sulfhydrylsilane, and epoxysilane.
- 5. The method of claim 4, whereby said silane is aminopropyltrimethoxysilane or mercaptopropyltrimethoxysilane.
- 6. The method of claim 1, whereby said step of subjecting said substrate to a crosslinking treatment includes subjecting said substrate to glutaraldehyde or N-γ-maleimidobutyryloxy succinimide ester.
- 7. The method of claim 1, whereby said substrate includes a fluidic channel.
- 8. The method of claim 7, whereby said fluidic channel is fabricated by silicon-based lithography.
- 9. The method of claim 1, further comprising,
d) binding said affinity ligand to said substrate.
- 10. The method of claim 9, whereby said affinity ligand is an antibody.
- 11. The method of claim 9, whereby said affinity ligand is an anti-cryptosporidium oocyst IgM.
- 12. A microfluidic affinity system comprising,
a) a substrate subjected to a plasma treatment, a silanization treatment, and a crosslinking treatment; and b) an affinity ligand bound to said substrate;
- 13. The microfluidic affinity system of claim 12, whereby said substrate is a silicon substrate.
- 14. The microfluidic affinity system of claim 13, whereby said silicon substrate is a polydimethylsiloxane substrate.
- 15. The microfluidic affinity system of claim 12, whereby said silanization treatment includes subjecting said substrate to a silane selected from the group comprising aminosilane, sulfydrylsilane, and epoxysilane.
- 16. The microfluidic affinity system of claim 15, whereby said silane is aminopropyltrimethoxysilane or mercaptopropyltrimethoxysilane.
- 17. The microfluidic affinity system of claim 12, whereby said crosslinking treatment includes subjected said substrate to glutaraldehyde or N-γ-maleimidobutyryloxy succinimide ester.
- 18. The microfluidic affinity system of claim 12, whereby said substrate includes a fluidic channel.
- 19. The microfluidic affinity system of claim 12, whereby said affinity ligand is an antibody.
- 20. The microfluidic affinity system of claim 12, whereby said affinity ligand is an anti-cryptosporidium oocyst IgM.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit, under 35 U.S.C. 119(e), of U.S. Provisional Application No. 60/406,312 filed Aug. 28, 2002, the contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60406312 |
Aug 2002 |
US |